"Primary source for Venture Funding and Angel Investors"
Where Hope Grows Stronger

Sarcomatrix, a specialty pharmaceutical company, is developing novel drugs to treat a variety of muscle wasting diseases, sarcopenia, cachexia and muscular dystrophies. Total market potential greater than $50B.

Project Image
Where Hope Grows Stronger
Sarcomatrix is set to transform DMD treatment within a $2 billion market, targeting a $18 billion opportunity by 2030 with innovative therapies. Backed by $8 million in NIH funds and investor support, we're advancing toward crucial trials.